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1032-130 Dobutamine-Induced Obstruction May Not Predict 
Exercise-Induced Obstruction in Hypertrophic 
Cardiomyopathy
Donogh F. McKeogh, Crispin H. Davies, Oregon Health & Science University, Portland, 
OR
Background: Alcohol septal ablation is increasingly used for the treatment of exertional
dyspnea in patients with hypertrophic cardiomyopathy with obstruction (HOCM). The
dobutamine (D)-provoked LV outflow pressure gradient (PG) is commonly used to deter-
mine which patients with HOCM should undergo the procedure.
Methods: To determine the clinical relevance of D-PG, we performed echocardiography
during both D infusion and incremental upright bicycle exercise (Ex) in 10 consecutive
HOCM patients referred for alcohol septal ablation.
Results: Mean age was 52 years, maximal D dose was 9.4 mcg/Kg/min, and maximal tol-
erated workload was 101 Watts. Mean data are as shown: 
* p < 0.05, ** p < 0.01, compared to D value
As compared with D, the average percentage increase in PG was much less with Ex 
(117% vs 326%) despite much greater increases in heart rate (HR) (74% vs 28%) and 
systolic blood pressure (SBP) (25% vs 8%). During Ex, patients achieved a much higher 
double product (20,147 vs. 10,123, p < 0.001) at a lower PG (73 vs. 104 mmHg, p < 
0.01). Patients reported that the level of exertion during testing exceeded that encoun-
tered in daily life, and their measured exercise capacity was greater than expected from 
reported NYHA class: 1.7 vs. 2.5 (p <0.05).
Conclusion: D-induced gradients are of uncertain clinical relevance in HOCM. When 
alcohol septal ablation is being considered exercise testing may be preferable to deter-
mine if a provocable PG is likely to contribute to a patient’s exertional dyspnea.
1032-131 Impaired Coronary Circulation in Patients With Apical 
Hypertrophic Cardiomyopathy: Noninvasive Analysis by 
Transthoracic Doppler Echocardiography
Ken Yoshida, Takeshi Hozumi, Yasuhiko Takemoto, Kenichi Sugioka, Hiroyuki Watanabe, 
Minoru Yoshiyama, Kazuhide Takeuchi, Junichi Yoshikawa, Osaka City University 
Medical School, Osaka, Japan
Background: Abnormal coronary flow and coronary flow reserve have been identified in
patients with hypertrophic cardiomyopathy (HCM). However, characteristics of coronary
circulation in patients with apical hypertrophic cardiomyopathy (ApHCM), that is a rela-
tively rare form of HCM, have not been fully assessed. Recent advancement in transtho-
racic Doppler echocardiography (TTDE) provides noninvasive assessment of coronary
flow velocity (CFV) pattern and reserve (CFVR) with coronary vasodilators in patients
with various cardiac diseases. Thus, we designed this study to examine the characteris-
tics of CFV and CFVR in patients with ApHCM. Methods: We analyzed the wall thickness
of apical hypertrophied myocardium and basal posterior wall, and CFV and CFVR in the
distal portion of the left anterior descending coronary artery (LAD) in 10 patients with
ApHCM (63 +/- 6 years) and 10 control subjects (61 +/- 6 years). The apical to posterior
wall ratio (AW/PW) and the characteristics of following CFV parameters at rest and dur-
ing hyperemia (intravenous ATP: 0.14mg/kg per minute) were measured; mean diastolic
velocity (MDV), time from beginning of diastole to peak velocity corrected by squared RR
interval (TPV), and CFVR defined as a ratio of hyperemic MDV to MDV at rest. Results: A
higher AW/PW and MDV, and a longer TPV were observed in ApHCM than those of con-
trol subjects at rest (1.7 +/- 0.1 versus 0.7 +/- 0.1, and 29 +/- 6 versus 17 +/- 5 cm/sec,
and 5.2 +/- 1.0 versus 3.4 +/- 0.6 msec; p< 0.01, respectively). CFVR in ApHCM was sig-
nificantly lower compared with in control subjects (1.8 +/- 0.4 versus 2.9 +/- 0.7; p<0.01),
whereas MDV during hyperemia was similar between ApHCM and control subjects (53 +/
- 13 versus 54 +/- 21 cm/sec). CFVR and MDV at rest in ApHCM showed significant cor-
relations with AW/PW in the left ventricle (AW/PW=0.51*CFVR + 4.29; r=-0.84; p<0.01,
and AW/PW=0.51*MDV + 2.48; r=0.74; p<0.05, respectively). Conclusion: CFV analysis
by TTDE revealed that coronary circulation in the LAD was impaired in ApHCM because
of increased resting coronary flow related to localized hypertrophy in the apical myocar-
dium.
1032-132 An Analysis of Patients With Hypertrophic Obstructive 
Cardiomyopathy and Persisting New York Heart 
Association Class III Symptoms During Long-Term 
Follow-Up After Septal Ablation
Dirk Welge, Lothar Faber, Hubert Seggewiss, Dieter Fassbender, Dieter Horstkotte, 
Heart Center North Rhine-Westphalia, Bad Oeynhausen, Germany, Leopoldina Hospital, 
Schweinfurt, Germany
Background and introduction: In about 90% of the patients (pts). with symptomatic hyper-
trophic obstructive cardiomyopathy (HOCM), symptoms and outflow gradient (LVOTG)
can significantly be reduced by septal ablation (PTSMA). Pts. with persisting heart failure
symptoms during long-term follow-up after PTSMA are not characterized sufficiently. We
analyzed our long-term cohort of 178 pts. treated between 1996 and 1998 with respect to
persisting or recurrent NYHA functional class III symptoms.
Results: Hospital mortality was 1.7% (VF, pulmonary embolism, and pericardial tampon-
ade in 1 pt. each). Mean CK rise was 599±300 U/l. A DDD-pacemaker (DDD-PM) had to
be implanted in 13 pts. (7%). Mean follow-up time is now 55±15 months, 8 pts. (5%) were
lost to follow-up. Out of the 167 cases analyzed, 12 pts. (7%) underwent a re-PTSMA and
4 (2%) a myectomy. These cases included, 156 pts. (88%) had complete elimination of
obstruction, and151 pts. (85%) reported sustained symptomatic improvement at their last
follow-up.
Persisting or recurrent class III symptoms, however, were reported by 16 pts. (10%).
LVOTG recurrence or persistence was the suspected reason in only 2 of these cases, 8
pts. were free from LVOT obstruction, and 6 had provocable gradients <60 mm Hg con-
sidered hemodynamically irrelevant. The leading reason for persisting class III symptoms
despite satisfactory LVOTG reduction were marked obesity (BMI>30/m2) in 5, severe
diastolic LV dysfunction in 5, and coexistent pulmonary disease in 4 pts. 9 pts. (5%) died
during long-term follow-up: due to stroke (n=3), extracardiac disease (n=3), or suspected
sudden cardiac death (n=3).
Conclusions: PTSMA results in a persistent LVOTG reduction and symptomatic improve-
ment during long-term follow up. Peri-interventional and long-term mortality seem to be
at least comparable to surgical myectomy. Pts. with marked obesity, coexistent pulmo-
nary disease, and advanced diastolic LV dysfunction are less likely to have symptomatic
benefit from LVOTG reduction, and need additional treatment of these abnormalities.
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1033-109 Assessing the Need for Repeat Baseline Exercise Tests 
in Heart Failure Patients: Early Experience From HF-
ACTION
Daniel R. Bensimhon, Stephen J. Ellis, Steven J. Keteyian, Ileana L. Pena, Dalane W. 
Kitzman, William E. Kraus, Lawton S. Cooper, Robin Boineau, Jerome L. Fleg, Robert S. 
McKelvie, Eric Leifer, Andrew Kao, David J. Whellan, Christopher M. O'Connor, Stuart D. 
Russell, for the HF-ACTION Investigators, Duke Clinical Research Institue, Durham, NC, 
Duke University Medical Center, Durham, NC
Background: Aerobic capacity is an important outcome in heart failure trials and is often
quantified by expired gas analysis during exercise testing. However, patient familiariza-
tion can lead to improvements in exercise parameters over serial testing. Thus, many tri-
als require multiple baseline tests. In clinical practice, however, a single test is routinely
used for prognosis or exercise prescription.
HF-ACTION is a multi-center randomized controlled trial designed to evaluate the effect
of exercise training on morbidity and mortality in 3,000 patients with an ejection fraction <
35% and NYHA class II-IV symptoms. The protocol specifies that two cardiopulmonary
exercise tests (CPXs) be conducted at baseline. After the first 100 subjects, an analysis
was planned to determine if multiple baseline tests are necessary; the results are
reported here.
Methods: Each subject underwent two maximal CPXs using a Modified Naughton proto-
col. Baseline tests were separated by > 48 hours but < seven days. Exercise time, VO2,
heart rate (HR), respiratory exchange ratio (RER), and rating of perceived exertion (RPE)
were measured. Quality control included investigator training, submission of sample
tests, and oversight by a core lab.
Results: n=85
Conclusion: With appropriate quality control, serial baseline exercise tests do not result 
in improvements in HRR or maximum aerobic capacity. Therefore, when peak VO2 and 
HRR are used as outcome measures or for exercise prescription, only a single baseline 
test is needed.
1033-110 Lowered Resting Heart Rate in High Fit Healthy 
Subjects Is Caused by a Lowered Intrinsic Heart Rate, 
Not by Elevated Parasympathetic Tone
Marianne Bootsma, Cees A. Swenne, Liming Han, Martin J. Schalij, Ernst E. Van der 
Wall, Leiden University Medical Center, Leiden, The Netherlands
Background. High fit subjects have a lower resting heart rate than low fit subjects.
Whether this is caused by an altered resting sympathetic or parasympathetic tone or by
an altered intrinsic heart rate is still a matter of debate.
Methods. We studied 21 low fit (VO2max 39.8 ± 6.3 ml×kg-1×min-1) and 23 high fit
(VO2max 57.6 ± 5.5 ml×kg-1×min-1) healthy young male subjects. Adopting the Rosen-
blueth-Simeone model for autonomic heart rate modulation, HR=m•n•IHR, we measured
resting heart rate (HR) and, with two-stage complete pharmacological autonomic block-
Resting HR Peak HR SBP rest (mmHg) SBP max
(mmHg)
PG rest
(mmHg)
PG max
(mmHg)
D 64 82 114 124 34 104
Ex 74* 126** 127 158* 42 73**
mean
T1
mean
T2
SD of 
(T2-T1)
% of 
tests
T2>T1
% of
tests 
T1>T2
p-value
(t-test)
Exercise time (secs) 599 626 83.6 65 31 0.003*
Peak VO2 (ml/kg/min) 14.84 14.92 1.99 55 37 0.71
Peak RER 1.11 1.12 0.08 63 33 0.33
Peak HR (bpm) 120 121 10.44 55 38 0.36
Peak RPE (Borg) 17.2 17.6 1.63 45 19 0.021*
Training HR based on 60% 
heart rate reserve (HRR) (bpm)
100.1 101.1 8.33 55 45 0.28
